Holocene Advisors LP Takes $49.09 Million Position in West Pharmaceutical Services, Inc. $WST

Holocene Advisors LP purchased a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 187,111 shares of the medical instruments supplier’s stock, valued at approximately $49,085,000. Holocene Advisors LP owned 0.26% of West Pharmaceutical Services as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services during the second quarter worth about $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of West Pharmaceutical Services by 193.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 95 shares during the last quarter. SJS Investment Consulting Inc. lifted its stake in West Pharmaceutical Services by 1,842.9% in the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 129 shares in the last quarter. MUFG Securities EMEA plc purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at about $47,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in West Pharmaceutical Services in the 3rd quarter worth about $47,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Up 2.1%

WST opened at $240.52 on Tuesday. The firm has a market capitalization of $17.34 billion, a price-to-earnings ratio of 35.42, a price-to-earnings-growth ratio of 2.50 and a beta of 1.17. The company’s 50 day simple moving average is $249.09 and its two-hundred day simple moving average is $261.93. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $322.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.02 and a quick ratio of 2.34.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The business had revenue of $805.00 million during the quarter, compared to analyst estimates of $795.70 million. During the same period in the prior year, the business earned $1.82 earnings per share. The business’s revenue was up 7.5% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio is presently 12.96%.

West Pharmaceutical Services declared that its board has approved a stock repurchase program on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 5.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

WST has been the subject of several research reports. Morgan Stanley initiated coverage on West Pharmaceutical Services in a research note on Monday, December 1st. They set an “equal weight” rating and a $285.00 price objective for the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $295.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $315.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Barclays reduced their price objective on West Pharmaceutical Services from $325.00 to $265.00 and set an “equal weight” rating for the company in a research note on Friday, February 13th. Finally, Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Buy” and an average target price of $314.56.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.